The financing of clinical genetics research by disease advocacy organizations: A review of funding disclosures in biomedical journals

American Journal of Medical Genetics, Part A

Volumn 152 A, Issue 12, 2010, Pages 3051-3056

  Sharp, Richard R ^a,b   Landy, David C ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; Ethics; Genetic research; Genetics; Research; Voluntary health agencies

Indexed keywords

ARTICLE; BIOMEDICINE; CLINICAL GENETICS; CYSTIC FIBROSIS; DATA BASE; DOWN SYNDROME; DUCHENNE MUSCULAR DYSTROPHY; EMBRYONIC STEM CELL; FINANCIAL MANAGEMENT; FUNDING; GENETIC DISORDER; GENETIC SUSCEPTIBILITY; GENETICS; HEALTH CARE ORGANIZATION; HEMOCHROMATOSIS; HEMOPHILIA A; HUNTINGTON CHOREA; MEDICAL LITERATURE; MEDICAL RESEARCH; OSTEOGENESIS IMPERFECTA; PHENYLKETONURIA; PRADER WILLI SYNDROME; PRIORITY JOURNAL; SICKLE CELL ANEMIA; TURNER SYNDROME;

CONSUMER ADVOCACY; CONSUMER ORGANIZATIONS; DISCLOSURE; GENETICS, MEDICAL; HUMANS; PERIODICALS AS TOPIC; RESEARCH SUPPORT AS TOPIC; TIME FACTORS;

EID: 78649653299     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.33767     Document Type: Article

References (27)

1. Bennett RL, Hart KA, O'Rourke E, Barranger JA, Johnson J, MacDermot KD, Pastores GM, Steiner RD, Thadhani R. 2002. Fabry disease in genetic counseling practice: Recommendations of the National Society of Genetic Counselors. J Genet Counsel 11: 121-146.
2. Birkhahn RH, Van Deusen SK, Okpara OI, Datillo PA, Briggs WM, Gaeta TJ. 2006. Funding and publishing trends of original research by emergency medicine investigators over the past decade. Acad Emerg Med 13: 95-101.
3. Cody JD. 2006. Creating partnerships and improving health care: The role of genetic advocacy groups. Genet Med 8: 797-799.
4. Collyar D. 2005. How have patient advocates in the United States benefited cancer research? Nat Rev Cancer 5: 73-78.
5. Dresser R. 1998. Setting priorities for science support. Hastings Cent Rep 28: 21-23.
6. Dresser R. 2001. When Science Offers Salvation: Patient Advocacy and Research Ethics. New York: Oxford University Press.
7. Faucett WA, Hart S, Pagon RA, Neall LF, Spinella G. 2008. A model program to increase translation of rare disease genetic tests: Collaboration education, and test translation program. Genet Med 10: 343-348.
8. Gelfman LP, Morrison RS. 2008. Research funding for palliative medicine. J Palliat Med 11: 36-43.
9. Gladman DD, Menter A. 2005. Introduction/overview on clinical registries. Ann Rheum Dis 64: ii101-ii102.
10. Hampton T. 2006. Rare disease research gets boost. JAMA 295: 2836-2838.
11. International Association of Patients' Organizations. 2010. International Association of Patients' Organizations Membership Criteria. Available at: (accessed on August 10, 2010).
12. Kent A. 2002. Patients+research=result! EMBO Rep 3: 707-708.
13. Kington RS. 2009. National Institutes of Health Guidelines on Human Stem Cell Research. Available at: (accessed on February 19, 2010).
14. Landy DC, Sharp RR. 2008. Conflicts of interest in bioethics: A response to our critics. Am J Bioeth 8: W1-W2.
15. Landy DC, Sharp RR. 2010. Examining the potential for exploitation by local intermediaries. Am J Bioeth 10: 12-13.
16. Ledbetter D. 2008. Gene patenting and licensing: The role of academic researchers and advocacy groups. Genet Med 10: 314-319.
17. Leslie M. 2006. Jumpstarting research into neglected diseases. Cell 127: 443-445.
18. Penissi E. 2000. Patients help track down disease gene. Science 288: 1565-1567.
19. Sharp RR, Scott AL, Landy DC, Kicklighter LA. 2008. Who is buying bioethics research? Am J Bioeth 8: 54-58.
20. Sharp RR, Yarborough M, Walsh JW. 2008. Ethical, Legal, Social Issues Working Group of the Alpha-1 Foundation. Responsible patient advocacy: Perspectives from the Alpha-1 Foundation. Am J Med Genet Part A 146A: 2845-2850.
21. Simon C, Mosavel M. 2010. Community members as recruiters of human subjects: Ethical considerations. Am J Bioeth 10: 3-11.
22. Terry SF, Boyd CD. 2001. Researching the biology of PXE: Partnering in the process. Am J Med Genet 106: 177-184.
23. Terry SF, Terry PF, Rauen KA, Uitto J, Bercovitch LG. 2007. Advocacy groups as research organizations: The PXE International example. Nat Rev Genet 8: 157-164.
24. Tunis SR, Stryer DB, Clancy CM. 2003. Practical clinical trials: Increasing the value of clinical research for decision making in clinical and health policy. JAMA 290: 1624-1632.
25. Uitto J. 2001. Patient advocacy groups partner genetic research, and forge the agenda. Trends Mol Med 7: 182-183.
26. Wästfelt M, Fadeel B, Henter J-I. 2006. A journey of hope: Lessons learned from studies on rare diseases and orphan drugs. J Intern Med 260: 1-10.
27. Zonno KD, Terry SF. 2009. Collaboration: The foundation for success in rare disease genetic test development. Genet Test Mol Biomark 13: 553-554.